Louisiana patient becomes first in state functionally cured of sickle cell disease
For most people, a hospital bell marks the end of treatment. For Daniel Cressy, it sounded more like clearance for takeoff.
On June 22, the 23-year-old from Metairie, Louisiana, stood inside Manning Family Children’s Hospital in New Orleans and rang the ceremonial bell after doctors declared him functionally cured of sickle cell disease.
It was a medical first with deep local meaning: Cressy became Louisiana’s first sickle cell gene-therapy patient to reach that milestone, and the hospital described him as the first person in the Gulf South to receive Casgevy’s CRISPR/Cas9 gene-editing therapy there.
But the moment was never just about medicine. Cressy has long dreamed of becoming a commercial pilot. For years, sickle cell disease kept that dream trapped behind pain, hospital stays, and uncertainty. Now, one bell in New Orleans may have opened the sky again.
What Happened in New Orleans
Cressy was diagnosed with sickle cell disease as an infant. As he grew older, Manning Family Children’s said he dealt with frequent severe pain episodes that sent him to emergency rooms and hospital beds when he should have been in classrooms or with friends. He worked to stay healthy, but the disease kept reaching into ordinary life.
Then came the possibility of gene editing. According to Manning Family Children’s, Cressy’s cells were collected in late 2025 and sent to Scotland, where they were genetically modified. The cells returned to New Orleans in March 2026.
Cressy received chemotherapy to clear out sickled cells, then had his edited cells infused back into his body on March 18. After about a month of inpatient recovery, he continued outpatient monitoring.
Three months after infusion, the hospital said his hemoglobin levels were the highest of his life. Cressy called the next chapter “Life 2.” In his own words, “Overcoming what seemed impossible became my greatest blessing.”
What “Functionally Cured” Means
Sickle cell disease changes red blood cells. Instead of staying round and flexible, the cells can become stiff and crescent-shaped. The CDC says those cells can lodge in small blood vessels, leading to pain, blocked blood flow, anemia, infection, pneumonia, acute chest syndrome, stroke, and kidney, liver, or heart disease.
A functional cure does not mean every inherited trace of the condition disappears from the body. It means the disease is no longer driving the painful crises and blood problems that ruled daily life. For patients like Cressy, the goal is healthy blood production strong enough to stop the sickling process from causing those severe episodes.
That is why the word “functional” matters. It is careful. It is medical. But for a patient who has lived through years of pain, hospital visits, and closed doors, it can also mean freedom.
How Gene Editing Works
Casgevy is built around CRISPR/Cas9 technology. The FDA approved Casgevy and Lyfgenia on December 8, 2023, as the first cell-based gene therapies for sickle cell disease in patients 12 and older. The FDA also said Casgevy was the first approved treatment using this type of genome editing technology.
The process is intense. Doctors collect the patient’s own blood stem cells. A lab edits those cells so they produce more fetal hemoglobin, a type of hemoglobin that helps prevent red blood cells from sickling.
The patient then receives high-dose chemotherapy to allow the bone marrow to make room for the edited cells. After infusion, the cells settle in the bone marrow and begin producing healthier blood cells.
This is not a quick shot or a simple pill. The FDA says both approved therapies require high-dose chemotherapy before infusion, and patients need long-term follow-up to track safety and effectiveness.
Still, the trial results were striking. In FDA-reviewed Casgevy data, 29 of 31 evaluable patients (93.5%) were free from severe vaso-occlusive crises for at least 12 consecutive months.
Why This Case Matters in Louisiana
The human story is Cressy. The public story is accessible.
The CDC says sickle cell disease affects about 100,000 people in the United States. More than 90% are non-Hispanic Black or African American, and an estimated 3% to 9% are Hispanic or Latino. The CDC also says life expectancy for individuals in the U.S. with sickle cell disease is more than 20 years shorter than average.
In Louisiana, the numbers bring the issue close to home. The Louisiana Department of Health says an average of 70 infants were born with sickle cell disease in the state from 2021 to 2024. Louisiana Medicaid covers about 3,000 people living with the condition each year.
That is why Cressy’s cure is not just a hospital headline. It shows that a treatment once available only through a narrow set of advanced centers can now reach families in the Gulf South. Manning Family Children’s says it is among a select group of programs nationally offering both FDA-approved gene-altering technologies for sickle cell disease.
The Hope Comes With Hard Questions
Medical firsts often arrive with celebration. Then come the hard details.
Casgevy and Lyfgenia are one-time treatments, but they are complex, expensive, and hard to deliver. They require specialized centers, cell collection, manufacturing, chemotherapy, hospital recovery, and careful follow-up. Families may also face insurance delays, travel barriers, time away from work, and fear about the treatment itself.
The access question matters because sickle cell disease has long carried a burden of stigma. The CDC says many people with the disease have trouble getting proper care and report feeling dismissed when they seek treatment.
In 2019, a CDC study of children and teens enrolled in Medicaid found that less than half received recommended stroke screening, and less than half of children ages 2 to 9 with sickle cell anemia used hydroxyurea.
That gap sits in the background of every breakthrough. A cure that exists on paper is not the same as a cure a family can reach.
What Experts Are Saying
FDA leaders framed the 2023 approvals as a major step for patients with limited options. Dr. Nicole Verdun, director of the FDA’s Office of Therapeutic Products, called sickle cell disease a “rare, debilitating and life-threatening blood disorder.” Dr. Peter Marks, then director of the FDA’s Center for Biologics Evaluation and Research, called the approvals an “important medical advance.”
At Manning Family Children’s, President and CEO Lucio A. Fragoso framed Cressy’s case through possibility, saying, “Curative gene therapy is restoring futures.”
That phrase fits this story because sickle cell disease affects more than just the blood. It affects time. It can decide which jobs feel possible, which trips feel safe, which schools feel manageable, and which dreams are delayed until the body cooperates.
What Readers Can Take Away
Cressy’s bell did not end the sickle cell story in Louisiana. It opened a new chapter.
For families living with the disease, his case offers something rare: proof that the future of sickle cell care can look different from the past. For doctors and hospitals, it shows that gene-editing medicine is moving from research promise into real treatment rooms. For policymakers and insurers, it raises the harder test: can a costly, specialized cure reach the communities that have carried this disease for generations?
Cressy wants to fly. That dream gives science a human shape. A blood disease once stood between him and the sky. Now, after a long treatment journey, the door is open again. The bell rang once in New Orleans. For many sickle cell families, the echo may last much longer.
Disclaimer – This list is solely the author’s opinion based on research and publicly available information. It is not intended to be professional advice.
Like our content? Be sure to follow us
